I agree, they need to allow EPS to grow and I believe this year and last may be their heaviest expansion and marketing in such a short period of time, which is good to make a major impact and let the rest follow. As time goes on they will have more brand recognition which will help replace marketing expenses. I am also excited to see their growth with Zushima, other drugs, and acquisitions over the next couple of years. I see nothing but positives for the growth of the company and price of the stock in due time.
Market Data 
Markets 
AI
